NCT04626752

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Multiple Myeloma (MM)

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

Detailed description

This is a study to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma. The Main research objectives: To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. The Secondary research objectives: To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	BCMA CAR-T	Volunteers will be treated with BCMA CAR-T cells
DRUG	Fludarabine	25mg/㎡ for D-4、D-3 and D-2
DRUG	Cyclophosphamide	500mg/㎡ for D-3 and D-2

Timeline

• Start date: 2020-04-01
• Primary completion: 2023-03-30
• Completion: 2023-03-30
• First posted: 2020-11-13
• Last updated: 2020-11-13

Locations

1 site across 1 country: China